WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998000126) TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/000126    International Application No.:    PCT/US1997/011570
Publication Date: 08.01.1998 International Filing Date: 27.06.1997
Chapter 2 Demand Filed:    21.01.1998    
IPC:
A61K 31/216 (2006.01)
Applicants: SEPRACOR, INC. [US/US]; 111 Locke Drive, Marlborough, MA 01752 (US)
Inventors: ABERG, Gunnar; (US).
McCULLOUGH, John, R.; (US)
Agent: HANSEN, Philip, E.; Heslin & Rothenberg, P.C., 5 Columbia Circle, Albany, NY 12203 (US)
Priority Data:
08/671,976 28.06.1996 US
Title (EN) TREATING URINARY INCONTINENCE USING (S)-OXYBUTYNIN AND (S)-DESETHYLOXYBUTYNIN
(FR) UTILISATION DE (S)-OXYBUTYNINE ET DE (S)-DESETHYLOXYBUTYNINE POUR TRAITER L'INCONTINENCE URINAIRE
Abstract: front page image
(EN)A method for treating urinary incontinence while avoiding concomitant liability of adverse effects associated with racemic oxybutynin is disclosed. The method comprises administering from 100 mg to 1 000 mg/day of (S)-oxybutynin, (S)-desethyloxybutynin or a pharmaceutically acceptable salt thereof, substantially free of the corresponding R enantiomer. Pharmaceutical compositions in the form of tablets, soft elastic gelatin capsules and transdermal devices comprising an acceptable carrier and up to 500 mg of (S)-oxybutynin or (S)-desethyloxybutynin are also disclosed.
(FR)Le procédé de l'invention permet de traiter l'incontinence urinaire tout en évitant le risque concomitant lié aux effets nocifs associés à l'oxybutynine racémique. Le procédé consiste à administrer entre 100 mg et 1 000mg par jour de (S)-oxybutynine ou de (S)-déséthyloxybutynine, ou un sel pharmaceutiquement acceptable desdits composés, sensiblement dépourvus de leur énantiomère R respectif. L'invention concerne aussi des compositions pharmaceutiques préparées sous forme de comprimés, de capsules de gélatine molles élastiques, ainsi qu'une trousse transdermique comprenant un transporteur acceptable et au maximum 500 mg de (S)-oxybutynine ou de (S)-déséthyloxybutynine.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)